Comparative Pharmacology
Head-to-head clinical analysis: LINACLOTIDE versus TRULANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LINACLOTIDE versus TRULANCE.
LINACLOTIDE vs TRULANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (cGMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.
Guanylate cyclase-C receptor agonist; increases intracellular cGMP, leading to chloride and water secretion into intestinal lumen and accelerated transit.
145 mcg orally once daily, at least 30 minutes before the first meal of the day.
3 mg orally once daily.
None Documented
None Documented
Approximately 9–10 hours (terminal half-life in plasma), supporting once-daily dosing.
Terminal elimination half-life is approximately 16 hours, supporting once-daily dosing.
Primarily fecal as intact peptide (95%); renal excretion of absorbed drug is minimal (<5%).
Primarily excreted in feces as unchanged drug (approximately 60%) and as metabolites; renal excretion is minimal (<3%).
Category C
Category C
Guanylate Cyclase-C Agonist
Guanylate Cyclase-C Agonist